[go: up one dir, main page]

PL2928884T3 - Nowe pochodne benzoimidazoli jako antagoniści EP4 - Google Patents

Nowe pochodne benzoimidazoli jako antagoniści EP4

Info

Publication number
PL2928884T3
PL2928884T3 PL13798684T PL13798684T PL2928884T3 PL 2928884 T3 PL2928884 T3 PL 2928884T3 PL 13798684 T PL13798684 T PL 13798684T PL 13798684 T PL13798684 T PL 13798684T PL 2928884 T3 PL2928884 T3 PL 2928884T3
Authority
PL
Poland
Prior art keywords
antagonists
benzimidazole derivatives
novel benzimidazole
novel
derivatives
Prior art date
Application number
PL13798684T
Other languages
English (en)
Inventor
Olaf Peters
Nico Bräuer
Thorsten Blume
Laak Antonius Ter
Ludwig Zorn
Jens Nagel
Stefan Kaulfuss
Gernot Langer
Joachim Kuhnke
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47325927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2928884(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL2928884T3 publication Critical patent/PL2928884T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
PL13798684T 2012-12-06 2013-12-03 Nowe pochodne benzoimidazoli jako antagoniści EP4 PL2928884T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195849 2012-12-06
EP13798684.0A EP2928884B1 (de) 2012-12-06 2013-12-03 Neuartige benzimidazolderivate als ep4-antagonisten

Publications (1)

Publication Number Publication Date
PL2928884T3 true PL2928884T3 (pl) 2017-11-30

Family

ID=47325927

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13798684T PL2928884T3 (pl) 2012-12-06 2013-12-03 Nowe pochodne benzoimidazoli jako antagoniści EP4

Country Status (40)

Country Link
US (1) US9708311B2 (pl)
EP (1) EP2928884B1 (pl)
JP (1) JP6367822B2 (pl)
KR (1) KR20150092248A (pl)
CN (1) CN104854098B (pl)
AP (1) AP3862A (pl)
AR (1) AR093840A1 (pl)
AU (1) AU2013354226B2 (pl)
BR (1) BR112015012555B1 (pl)
CA (1) CA2893630C (pl)
CL (1) CL2015001508A1 (pl)
CR (1) CR20150296A (pl)
CU (1) CU20150056A7 (pl)
CY (1) CY1119200T1 (pl)
DK (1) DK2928884T3 (pl)
EA (1) EA028830B1 (pl)
EC (1) ECSP15022555A (pl)
ES (1) ES2637738T3 (pl)
GT (1) GT201500138A (pl)
HR (1) HRP20171200T1 (pl)
IL (1) IL239026A0 (pl)
JO (1) JO3431B1 (pl)
LT (1) LT2928884T (pl)
MA (1) MA38146B1 (pl)
ME (1) ME02950B (pl)
MX (1) MX2015007135A (pl)
MY (1) MY175272A (pl)
NI (1) NI201500077A (pl)
NZ (1) NZ707825A (pl)
PE (1) PE20151065A1 (pl)
PH (1) PH12015501289B1 (pl)
PL (1) PL2928884T3 (pl)
PT (1) PT2928884T (pl)
RS (1) RS56121B1 (pl)
SI (1) SI2928884T1 (pl)
TN (1) TN2015000250A1 (pl)
TW (1) TWI613198B (pl)
UA (1) UA115576C2 (pl)
UY (1) UY35177A (pl)
WO (1) WO2014086739A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
MA39211B1 (fr) * 2013-12-24 2019-01-31 Bristol Myers Squibb Co Composés tricycliques comme agents anti-cancers
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
CN104326937B (zh) 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
PT3203840T (pt) 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
WO2018162562A1 (en) * 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020014445A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Ep4 inhibitors and synthesis thereof
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
WO2021225955A1 (en) * 2020-05-04 2021-11-11 Astex Pharmaceuticals, Inc. Iap antagonist compounds and intermediates and methods for synthesizing the same
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
KR102708701B1 (ko) * 2021-12-27 2024-09-24 에이치케이이노엔 주식회사 벤즈이미다졸 유도체의 제조방법
CN116789646B (zh) * 2023-07-12 2025-07-08 广西医科大学 咔唑-苯并咪唑偶联类化合物及其应用
WO2025135108A1 (ja) * 2023-12-22 2025-06-26 Ａｇｃ株式会社 新規なｅｐ４アンタゴニスト

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
ATE442147T1 (de) 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
MXPA04009243A (es) 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
KR20050026031A (ko) * 2002-07-31 2005-03-14 유로-셀티큐 에스.에이. 아릴 치환된 벤즈이미다졸 및 나트륨 채널 차단제로서이의 용도
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
KR20050084621A (ko) 2002-11-15 2005-08-26 티보텍 파마슈티칼즈 리미티드 항­감염성 화합물로서의 치환된 인돌피리디늄
US6949564B2 (en) 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
PT1603893E (pt) 2003-01-29 2008-08-21 Asterand Uk Ltd Antagonistas dos receptores ep4
EP1613618A2 (en) 2003-04-03 2006-01-11 Neurosearch A/S BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX
TW200512147A (en) 2003-07-25 2005-04-01 Black Clawson Converting Machinery Inc Method and apparatus for splicing webs
CA2536870C (en) 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
RU2006137076A (ru) 2004-04-20 2008-04-27 Пфайзер Продактс Инк. (Us) Комбинации, содержащие лиганды рецептора альфа-2-дельта
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP1756043B1 (en) 2004-05-04 2009-07-01 RaQualia Pharma Inc Ortho substituted aryl or heteroaryl amide compounds
AU2005325497A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
US7732447B2 (en) * 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
ES2421453T3 (es) 2006-08-11 2013-09-02 Merck Frosst Canada Ltd Derivados de tiofenocarboxamida como ligandos del receptor EP4
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
US20100204487A1 (en) 2007-08-09 2010-08-12 Ian Davies Process for making thiophene carboxamide derivatives
EP2320906B1 (en) 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
US20100249125A1 (en) 2009-03-31 2010-09-30 The Texas A&M University System Inhibition of prostglandin e2 receptors for the treatment of endometriosis
WO2010124097A2 (en) 2009-04-22 2010-10-28 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CN102770159A (zh) * 2010-02-22 2012-11-07 拉夸里亚创药株式会社 Ep-4受体拮抗剂在治疗il-23介导疾病中的用途
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物

Also Published As

Publication number Publication date
BR112015012555B1 (pt) 2022-02-15
CN104854098A (zh) 2015-08-19
US20160214977A1 (en) 2016-07-28
TWI613198B (zh) 2018-02-01
PH12015501289B1 (en) 2019-02-13
SI2928884T1 (sl) 2017-09-29
JP2016501241A (ja) 2016-01-18
PT2928884T (pt) 2017-08-25
JO3431B1 (ar) 2019-10-20
EA028830B1 (ru) 2018-01-31
ES2637738T3 (es) 2017-10-16
CN104854098B (zh) 2018-01-09
AR093840A1 (es) 2015-06-24
MY175272A (en) 2020-06-17
CA2893630A1 (en) 2014-06-12
TW201422608A (zh) 2014-06-16
CY1119200T1 (el) 2018-02-14
GT201500138A (es) 2017-10-05
AP3862A (en) 2016-10-31
KR20150092248A (ko) 2015-08-12
CR20150296A (es) 2015-08-10
AU2013354226B2 (en) 2017-09-14
CL2015001508A1 (es) 2015-07-24
JP6367822B2 (ja) 2018-08-01
AU2013354226A1 (en) 2015-06-18
PE20151065A1 (es) 2015-08-19
WO2014086739A1 (de) 2014-06-12
MA38146A1 (fr) 2018-01-31
ECSP15022555A (es) 2016-01-29
HRP20171200T1 (hr) 2017-12-15
EP2928884A1 (de) 2015-10-14
LT2928884T (lt) 2017-08-25
CU20150056A7 (es) 2015-10-27
TN2015000250A1 (en) 2016-10-03
UA115576C2 (uk) 2017-11-27
DK2928884T3 (en) 2017-09-11
EA201591087A1 (ru) 2015-12-30
MX2015007135A (es) 2016-02-05
ME02950B (me) 2018-07-20
EP2928884B1 (de) 2017-05-24
IL239026A0 (en) 2015-07-30
AP2015008463A0 (en) 2015-05-31
BR112015012555A2 (pt) 2017-07-11
UY35177A (es) 2014-06-30
NZ707825A (en) 2019-06-28
MA38146B1 (fr) 2018-08-31
HK1210139A1 (en) 2016-04-15
PH12015501289A1 (en) 2015-08-24
CA2893630C (en) 2021-02-23
NI201500077A (es) 2016-02-15
US9708311B2 (en) 2017-07-18
RS56121B1 (sr) 2017-10-31

Similar Documents

Publication Publication Date Title
AP3862A (en) Novel benzimidazole derivatives as ep4 antagonists
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
PL2877467T3 (pl) 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
PT2917217T (pt) Benzimidazoles tricíclicos substituídos como inibidores de quinases
IL236087A0 (en) n–aryltriazole compounds as lpar antagonists
IL236088A0 (en) n-Alkyltriazole compounds as lpar antagonists
EP2832734A4 (en) HETEROCYCLIC COMPOUND
ZA201504980B (en) Heterocyclic compound
IL239109B (en) New quinolone derivatives
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
PT2912041T (pt) Inibidores de bace
IL232503A (en) H2 - Indazoles as antagonists of the ep2 receptor
EP2914597A4 (en) PYRAZOLOPYRIDINONE DERIVATIVES AS TTX-S-BLOCKER
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
PL2814825T3 (pl) Dihydrofuranowe pochodne azetydyny jako środki przeciwpasożytnicze